Lord, Abbett & Co. LLC Day One Biopharmaceuticals, Inc. Transaction History

Lord, Abbett & Co. LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Oct 07, 2024	SELL	$12.75 - $23.41 $1.32 Million - $2.43 Million	-103,738 Reduced 20.49%	402,440 $5.38 Million
Q1 2023 May 12, 2023	SELL	$12.75 - $23.41 $1.32 Million - $2.43 Million	-103,738 Reduced 20.49%	402,440 $5.38 Million
Q4 2022 Oct 07, 2024	BUY	$18.77 - $22.0 $9.5 Million - $11.1 Million	506,178 New	506,178 $10.9 Million
Q4 2022 Feb 10, 2023	BUY	$18.77 - $22.0 $36,169 - $42,394	1,927 Added 0.38%	506,178 $10.9 Million
Q3 2022 Nov 14, 2022	BUY	$16.44 - $26.57 $8.29 Million - $13.4 Million	504,251 New	504,251 $10.1 Million

181

84.2M

148K

218K

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $956M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.